FOXP1 and nasopharyngeal carcinoma: Collectively, these data demonstrate that EBV-miR-BART11 or FOXP1 may serve as potential diagnostic or prognostic markers in NPC or GC, and may represent important targets for EBV-related cancer immunotherapy.